Targeting of hematologic malignancies with PTC299, a novel potent inhibitor of dihydroorotate dehydrogenase with favorable pharmaceutical properties

Article abstract of DOI:10.1158/1535-7163.MCT-18-0863

PTC299 was identified as an inhibitor of VEGFA mRNA translation in a phenotypic screen and evaluated in the clinic for treatment of solid tumors. To guide precision cancer treatment, we performed extensive biological characterization of the activity of PTC299 and demonstrated that inhibition of VEGF production and cell proliferation by PTC299 is linked to a decrease in uridine nucleotides by targeting dihydroorotate dehydrogenase (DHODH), a rate-limiting enzyme for de novo pyrimidine nucleotide synthesis. Unlike previously reported DHODH inhibitors that were identified using in vitro enzyme assays, PTC299 is a more potent inhibitor of DHODH in isolated mitochondria suggesting that mitochondrial membrane lipid engagement in the DHODH conformation in situ is required for its optimal activity. PTC299 has broad and potent activity against hematologic cancer cells in preclinical models, reflecting a reduced pyrimidine nucleotide salvage pathway in leukemia cells. Archived serum samples from patients treated with PTC299 demonstrated increased levels of dihydroorotate, the substrate of DHODH, indicating target engagement in patients. PTC299 has advantages over previously reported DHODH inhibitors, including greater potency, good oral bioavailability, and lack of off-target kinase inhibition and myelosuppression, and thus may be useful for the targeted treatment of hematologic malignancies.

Full text of DOI:10.1158/1535-7163.MCT-18-0863

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of
Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties
Liangxian Cao1*, Marla Weetall1, Christopher Trotta1, Katherine Cintron1, Jiyuan Ma1, Min Jung Kim1,
Bansri Furia1, Charles Romfo1, Jason D. Graci1, Wencheng Li1, Joshua Du1, Josephine Sheedy1, Jean
Hedrick1, Nicole Risher1, Shirley Yeh1, Hongyan Qi1, Tamil Arasu#a, Seongwoo Hwang1, William
Lennox1, Ronald Kong1, Janet Petruska1, Young-Choon Moon1, John Babiak1, Thomas W. Davis#b,
Allan Jacobson2, Neil G. Almstead1, Art Branstrom1, Joseph M. Colacino1, Stuart W. Peltz1
1. PTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ 07080
2. Department of Microbiology and Physiological Systems, University of Massachusetts Medical
School, 368 Plantation Street, Worcester, MA 01655
#a Current address: US Food and Drug Administration, 10 Waterview Blvd, 3rd Floor, Parsippany, NJ
07054;
#b Current addresses: PMV Pharmaceuticals Inc., Cedar Brook Corporate Center, 8 Clarke Drive,
Cranbury Township, New Jersey 08512
Running title: PTC299 is a novel potent DHODH inhibitor
Keywords: Dihydroorotate dehydrogenase (DHODH); Vascular endothelial growth factor A (VEGFA);
Hematologic Malignancies; Drug mechanism; Cancer therapy
Corresponding author:
Liangxian Cao, MD
PTC Therapeutics
South Plainfield, NJ 07080, USA
Email: lcao@ptcbio.com; Tel: 908 912 9132; Fax: 908 222 0567
1
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
Conflict of interest statement: The authors are or were employed by PTC Therapeutic and have
received salary compensation for time, effort, and hold or held financial interest in the company. Travel
expenses related to attendance at scientific conferences to present data were reimbursed by PTC
Therapeutics, Inc. All patents related to the work presented here are held by PTC Therapeutics, Inc.
Word count: about 6000 words (including introduction, result, discussion, conclusion and figure
legends)
Total number of figures: five
2
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
ABSTRACT
PTC299 was identified as an inhibitor of VEGFA mRNA translation in a phenotypic screen and
evaluated in the clinic for treatment of solid tumors. To guide precision cancer treatment, we performed
extensive biological characterization of the activity of PTC299 and demonstrated that inhibition of
VEGF production and cell proliferation by PTC299 is linked to a decrease in uridine nucleotides by
targeting dihydroorotate dehydrogenase (DHODH), a rate limiting enzyme for de novo pyrimidine
nucleotide synthesis. Unlike previously reported DHODH inhibitors that were identified using in vitro
enzyme assays, PTC299 is a more potent inhibitor of DHODH in isolated mitochondria suggesting that
mitochondrial membrane lipid engagement in the DHODH conformation in situ is required for its
optimal activity. PTC299 has broad and potent activity against hematological cancer cells in preclinical
models, reflecting a reduced pyrimidine nucleotide salvage pathway in leukemia cells. Archived serum
samples from patients treated with PTC299 demonstrated increased levels of dihydroorotate, the
substrate of DHODH, indicating target engagement in patients. PTC299 has advantages over previously
reported DHODH inhibitors, including greater potency, good oral bioavailability and lack of off-target
kinase inhibition and myelosuppression, and thus may be useful for the targeted treatment of
hematologic malignancies.
3
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
INTRODUCTION
De novo pyrimidine nucleotide biosynthesis is activated in proliferating cancer cells in response to an
increased demand for synthesis of DNA, RNA and phospholipids by activation of oncogenic pathways
such as Myc, PI3K, PTEN and mTOR(1-5). DHODH, located on the surface of the inner mitochondrial
membrane, catalyzes the fourth enzymatic step, the ubiquinone-mediated oxidation of dihydroorotate to
orotate in the de novo pyrimidine synthesis pathway(6). DHODH is a validated therapeutic target for the
treatment of autoimmune diseases such as rheumatoid arthritis(7, 8). Inhibition of DHODH was shown
in preclinical studies to prevent growth of many types of cancers (9-13). Moreover, it was demonstrated
that inhibition of DHODH induces differentiation of acute myeloid leukemia cells(14-16).
Pharmacologic inhibition of de novo pyrimidine synthesis sensitizes triple negative breast cancer cells
to genotoxic chemotherapy agents and reduces chemotherapy resistance(2). DHODH inhibitors such as
teriflunomide, brequinar and vidofludimus, have been considered for use in oncology(17-20), but their
use may be limited due to a narrow therapeutic window as a result of lesser potency and/or off-target
activities such as their inhibition of kinases(21, 22).
There is great interest in the discovery and development of new DHODH inhibitors for therapeutic uses
(23, 24). These efforts have mainly relied on in vitro enzyme assays to define and optimize activity, in
which the purified enzyme conformation may differ from that found in the cells due to lack of membrane
lipids in the assay(25). Recently, it was demonstrated that DHODH attaches to the inner mitochondrial
membrane by binding charged phospholipids which stabilize the flexible substrate- and drug-binding
site, suggesting that the design and development of novel inhibitors that additionally engage in lipid
interactions may represent a promising approach to targeting DHODH in vivo(26).
PTC299 was identified as an inhibitor of the translation of VEGFA mRNA using PTC Therapeutics’
proprietary GEMSTM technology phenotypic screening platform(27). PTC299 was in clinical trials for
the treatment of solid tumors (28, 29) and is currently being reevaluated for use in hematologic cancers.
To guide safe and effective precision cancer treatment, we performed extensive biochemical
characterization of PTC299 and demonstrated that it interacts with and inhibits dihydroorotate
dehydrogenase (DHODH), a rate limiting enzyme in the de novo biosynthesis of pyrimidine
nucleotides(5). Inhibition of VEGFA production by PTC299 is a downstream effect of inhibiting de
novo pyrimidine synthesis as it can be completely rescued by exogenously added uridine but not by
other nucleosides. Collectively, PTC299 represents a novel class of potent DHODH inhibitors and our
4
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
data demonstrate the potential of PTC299 as a treatment option to address unmet needs in cancers, such
as leukemia and lymphoma, that have lower levels of uridine salvage activity and thus rely on the de
novo biosynthesis of pyrimidine nucleotides for survival and rapid proliferation.
METHODS
General methods.
DNA constructs were generated using standard procedures as reported previously (27). VEGFA 5’- and
3’- UTRs were amplified from human genomic DNA (Clontech) while the VEGFA165 open reading
frame from RNA derived from HeLa cells incubated under hypoxia (1% oxygen) was amplified by
RT-PCR. DNAs generated with PCR were confirmed by DNA sequencing.
PTC299, PTC-371, GSK983 and vidofludimus (4SC-101) were synthesized at PTC Therapeutics; for
details, see the Supplementary Materials and Methods in the Supplementary Data file. Brequinar
(SML0113) and teriflunomide (SML0936) were purchased from Sigma, while pyrazofurin-MP
(P61-B01A) was purchased from TriLink Biotechnologies.
Cell culture
Tumor cell lines, except for MOLM-13 which were obtained from Dr. Kensuke Kojima in July 2015
(Saga University, Japan) and Huh-7 which were obtained in February 2001 from the Stuart Peltz
laboratory at University of Medicine and Dentistry of New Jersey (now Rutgers University, New
Jersey), were purchased from ATCC and were maintained in DMEM (adherent cells) or RPMI-1640
(suspension cells) supplemented with 10% fetal bovine serum (FBS), penicillin (50 IU/mL), and
streptomycin (50 µg/mL). Culture media and supplement agents were purchased from (Gibco BRL,
Invitrogen). Cells bought from ATCC were expanded and frozen at early passages. Cells were typically
used for studies within two to five weeks after thawed from frozen stocks. Cells that were cultured for
more than two months (about 20 passages) were discarded. Patient derived AML cells, purchased from
AllCells (January 2017), Inc and Champions Oncology, Inc (April 2017), were cultured in StemSpan
medium (Stemcell Technologies, Vancouver). Cell lines in culture were routinely verified once per
month to be mycoplasma free assayed by using the MycoAlert™ Mycoplasma Detection Kit (Cat#:
LT07-318, Lonza, USA). The 240 cell lines used for screening of PTC299 activity were authenticated
with STR profiling and mycoplasma tested by the CRO (Crown Bioscience, Shanghai, China),
5
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
otherwise we did not perform any additional cell line authentication in house. The information on the
source of cells and when they were obtained can be found in Supplementary Table S1.
Stable cell lines were generated as reported previously (27). Briefly, plasmid DNA was transfected into
HT1080 cells using Fugene-6 transfection reagent (Roche Diagnostics GmbH), followed by selection
with 200 µg/mL hygromycin for luciferase stable cell lines or 200 µg/mL Zeocin (Invitrogen) for V5 tag
stable cells in the culture medium.
Western blot analysis.
Western blot was performed as reported previously(27). Antibody (C1) specific for VEGFA was
purchased from Santa Cruz Biotechnologies, CA (1:200 dilution); Antibody specific for human β-actin
was purchased from Abcam (1:10000 dilution); Antibody specific for V5-tag was purchased from
Invitrogen (1:5000 dilution). Antibody specific for DHODH was purchased from Proteintech (Cat#:
14877-1-AP, 1:500 dilution); and antibody specific for human prohibitin was purchased from Thermo
Scientific (Cat#: PA5-12274 and PA5-14133, 1:1000 dilution). Immunodetection was done using the
corresponding secondary antibodies conjugated with infrared dyes or horseradish peroxide. The
expression levels of proteins were detected with Odyssey (LI-COR) or using enhanced
chemiluminescence (Pierce, Rockford, IL).
Determination of ELISA EC50 and cytotoxicity CC50 values: All ELISAs were performed using
commercially available ELISA kits (R&D Systems) according to the manufacturer’s instructions. The
screen of 240 cell lines was performed at Crown Bioscience (Shanghai, China). Cells were treated with
PTC299 at a series of doses for 72 hours and the inhibition of cell proliferation was determined using a
standard assay, CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Madison, WI) that
measures total cellular adenosine triphosphate (ATP) concentrations as an indicator of cell viability.
Data generated from ELISA or cytotoxicity studies were plotted with Prism software. A sigmoidal dose
response with a variable slope regression curve was generated for each compound. Maximal and
minimal inhibition were set at 100% and 0%, respectively, and CC50 values were calculated after curve
fitting using the Prism software.
35S-labeling and Immunoprecipitation. HT1080 cells harboring either the VEGFA
5'-UTR-VEGFA165-V5 construct or the control VEGFA165-V5 were treated for 8 hours with vehicle
alone (0.5% DMSO) or vehicle with 100 nM PTC299, then incubated with 35S-labeled methionine and
cysteine for approximately 4 hours in the presence or absence of the protein transporter inhibitor
6
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
brefeldin A or the proteasome inhibitor MG-132. Equal amounts of supernatant or the cell extracts were
immunoprecipitated with the anti-V5 antibody (Invitrogen). The immunoprecipitated products were
resolved by 4-20% gradient SDS-PAGE and exposed to Kodak Biomax MR film.
Human tumor xenograft studies. All studies involving animals were performed in accordance with
guidelines promulgated by the American Association for Accreditation of Laboratory Animal Care with
the oversight of the animal use and care committees at Rutgers University. Subcutaneous tumor
xenograft studies were performed as reported previously(27). For systemic leukemia lethality model,
male NOD-SCID mice were inoculated with MOLT-4 human ALL tumor cells (1 x 107 cells in 200 µL
of PBS) by intravenous (IV) injection. Eight days after tumor inoculation, mice were randomized into
two groups (10 mice per groups) and treated with compounds as indicated in the results. The mice were
observed until moribund, at which time they were euthanized. At 2- and 4-weeks post-inoculation,
whole blood was obtained from 5 mice per group by retro-orbital bleeding, stained with an antibody
against human CD45, and the number of CD45-positive cells was determined by FACs analysis.
Immunohistochemistry. Tumor samples were cut into pieces of less than 3 mm in thickness and placed
in a zinc fixative for 24 hours. Paraffin sections were prepared by American HistoLab, Inc. using
standard procedures. Mouse endothelial cells were stained with rat anti-mouse CD31 monoclonal
antibody MEC13.3 (BD Pharmingen, CA) and detected with a rabbit anti-rat IgG HRP detection kit
according to the manufacturer’s instructions (BD Pharmingen, CA).
Transcriptome Profiling with Microarrays. PTC299-resistant and parent HT1080 cells were seeded
in 6-well plates (5 x 105 cells/well) and incubated overnight. Four replicates of cells for each cell type
were performed. Total RNA was purified with RNeasy Mini Kit (Qiagen) according to the
manufacturer’s instructions. cRNA was prepared according to the standard Affymetrix protocol. cRNA
was hybridized at 45oC for 16 h on a GeneChip Human Genome U133 plus 2.0 Array. GeneChips were
analyzed using the Affymetrix scanner. Data analysis was performed using Transcriptome Analysis
Console (TAC) Software (Thermo Fisher Scientific). The MAS5 normalization method was used.
ANOVA was used for statistical evaluation.
Quantification of pyrimidine nucleotides in PTC299 treated cells
Cells in log phase growth were cultured in 10 cm dishes (4 x 106 cells/dish) with glutamine free DMEM
containing 1g/L glucose, 10% FBS, penicillin (50 IU/mL), streptomycin (50 µg/mL) and 1 mM
15N-glutamine (Sigma, Cat#: 490024). After culturing for the indicated time in the presence of
7
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
compounds or vehicle control (0.5% DMSO), the cells were washed once with 5 mL cold PBS,
harvested and lysed in 0.5 mL cold distilled H2O plus 1 mL -80oC methanol using a plastic cell scraper.
The cell lysates were then centrifuged at 10,000 x g for 15 minutes at 4oC, and the supernatant was
collected for LC-MS/MS analysis of the 15N-labelled de novo pyrimidine nucleotide metabolites.
LC-MS/MS detection of metabolites
Quantification of 15N-labelled de novo synthesized pyrimidine nucleotides was carried out on an Accela
pump and a PAL auto-sampler coupled to a TSQ Quantum Ultra mass spectrometer. The mass
spectrometer was equipped with a heated electrospray ionization source operated in negative-ion mode
(Thermo Fisher Scientific, Waltham, MA). The ion spray voltage was set at 2500 V, capillary
temperature at 350oC, vaporizer temperature at 300oC; sheath gas pressure at 50 units and auxiliary gas
pressure at 5 units. A Thermo Fisher Scientific Hypercab column (3 µm, 50 x 2.1 mm) was used and
maintained at 50°C for metabolite separation. Mobile phase A was 10 mM NH4HCO3 in water, pH 9.4,
and mobile phase B was 10 mM NH4HCO3 in ACN-water (9:1). The flow rate was set at 0.50 mL/min.
Ion transitions monitored were at m/z 156.0 → m/z 112.0 for 15N-orotic acid, m/z 158.0 → m/z 114.0 for
15N-dihydrorotic acid, m/z 324.0 → m/z 79.0 for 15N- monophosphate uridine (UMP).
Conjugation of PTC299 or PTC-371 to Sephorose-6B beads
PTC299 or its inactive enantiomer PTC-371, was conjugated to the epoxy-activated Sepharose 6B
according to the manufacturer’s instructions (GE healthcare cat. # 17-0480-01). Briefly, 1 gram of
epoxy-activated Sepharose 6B was stirred in water (20 mL) for 2h at RT, then filtered. The wet
Sepharose 6B was diluted with pH 11 phosphate/NaOH buffer (5 mL). To a solution of 1 mM
4-chlorophenyl
(S)-6-chloro-1-(4-hydroxyphenyl)-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]
indole-2-carboxylate in DMF (12 mL) at 40oC was added the Sepharose 6B in phosphate/NaOH buffer.
The reaction mixture was stirred further for 24 hours at 40oC. The Sepharose 6B-PTC299 product was
filtered and washed with DMF (100 mL), water (100 mL), pH 4 buffer (100 mL), pH 11 buffer (100 mL),
water (100 mL), and 0.5M NaCl/water. Sepharose 6B-PTC-371 was prepared with 4-chlorophenyl
(R)-6-chloro-1-(4-hydroxyphenyl)-1,3,4,9-tetrahydro-2H-pyrido-[3,4-b] indole-2-carboxylate using
above reaction procedures.
Pull-down of proteins that are specifically bound to PTC299-conjugated beads
8
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
Cells in log phase growth were washed with cold PBS once and then collected by trypsin digestion.
After centrifugation at 1200 rpm for 5 minutes, the cells were re-suspended in lysis buffer (PBS + 0.5%
Triton X100 + 1x proteinase inhibitors (Halt, Roche, Cat#: 78440) and incubated on ice for 10 minutes;
supernatants were collected after passing cells through a 22-gauge needle 10 times and centrifuging at
13,000 rpm for 15 min to remove cell debris. Subsequently, 1 mL of cell lysate solution (2 mg/mL
protein) was added to each reaction tube containing 25 l (packed volume) PTC299- or the
R-enantiomer control (PTC-371) beads and incubated for 2 hours at 4oC with gentle agitation on a
rotator; after three washes with 1 mL washing Buffer, 5 min/each, the protein bound with beads were
eluted with indicated buffer as shown in the Results section. Proteins in the eluted samples were verified
by western blot analysis.
Mitochondria isolated from cultured K562 cells as source of DHODH for in vitro enzyme
inhibition studies
Mitochondria were isolated from K562 cells in log phase growth using a Dounce homogenizer as
reported (30). The isolated mitochondria in the supernatant were pelleted at 12,000g for 15 min and
re-suspended in 1 mL 1x MS homogenization buffer for analysis of downstream DHODH activity as
described below.
In vitro DHODH activity assays
The chromogen reduction assay was carried out as previously reported(31). DHODH activity was
determined in the presence of compounds or vehicle control using the standard colorimetric DHODH
continuous assay in which the oxidation of dihydroorotic acid (DHO) and the subsequent coupled
reduction of ubiquinone is measured by monitoring the reduction of 2,6-dichlorophenolindophenol
(DCIP) on a BioTek Power Wave XS2. The velocity for each reaction was derived using the GEN5
software.
Docking analysis
Software Sybyl X 2.1.1 was used to prepare ligand structures. Ligands used in docking procedures were
imported as SDF 3D format which were processed using Pipeline Pilot. Protein crystal structures were
downloaded from the Protein Data Bank (PDB; http://www.rcsb.org/). Protein structure preparations
were performed using the standard protocol of Sybyl X 2.1.1, and the resulting structures were saved as
SYBYL ‘‘.mol2’’ files. The pockets Protocols were generated using standard fully automated
9
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
Surflex-Dock procedures(32). Sybyl provides a docking score for each docked conformation, which
includes two parts: an affinity score (-logKd) and a crash score (also pKd units). The crash score is the
degree of inappropriate penetration into the protein by the ligand as well as the degree of internal
self-clashing that the ligand is experiencing. The top docking scores for each ligand were used for
comparison.
The Docking Mode was set as Surflex_Dock GeomX(SFXC). Input options were set to allow 3D
Coordinate Generation, if necessary. Protein movement was set to allow for the flexibility of protein
atoms whose van der Waals surface distances from ligand atoms are < 4 Å and for the adaptation of the
active site conformation to the docked ligand. The covalent force field weighting of the ligand was set to
1.0, while the covalent force field weighting of the protein was set to 0.6 to allow heavy atoms to move.
The maximum number of poses was set to 10 to optimize and rescore each ligand after a docking run that
included protein movement. Additional Starting Conformations per Molecule were set to 6 (GeomX).
The maximum number of conformations per fragment to be submitted to the docking procedure was set
to 20. The Maximum Number of Poses per Ligand was set to 20. The minimum RMSD
(Root-Mean-Square Distance) between Final Poses was set to 0.50. The Sybyl version of the AMBER7
FF99 Force Field was used for energy calculations(33).
Statistical analysis. Data are the mean ± SD or SEM as indicated for quantitative experiments. For
statistical analysis, p-values were derived using unpaired Student’s t-tests for any study with only two
groups presented. Otherwise, comparisons of groups were performed on log-transformed data using a
one-way ANOVA test. All analyses were made using GraphPad Prism Software.
Data availability. All data generated or analyzed during this study are included in this article and its
supplementary information files. Additional information is available from the corresponding author
upon request.
RESULTS
PTC299 was identified from a phenotypic screen and chemical optimization as an inhibitor of
VEGFA protein synthesis
Using the contextual regulation of the production of VEGFA in the tumor cell imparted by critical
elements in the 5'- and 3'-UTRs of the VEGFA mRNA, we initiated a drug discovery program using
PTC Therapeutics’ proprietary GEMSTM technology phenotypic screening platform(27). Subsequently,
10
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
structure-activity-relationship (SAR) studies led to the identification of PTC299 (Fig. 1A) as a clinical
development candidate for cancer therapy. PTC299 is the pharmacologically active S-enantiomer of
4-chlorophenyl
(1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydro-2H-beta-carboline-2-carboxylate (synthesis of
PTC299 (5) and intermediates 1-4 shown in Supplementary Fig. S1A). Similar to the compounds
identified in a high throughput screen as previously described(27), biological characterization suggested
that PTC299 inhibited VEGFA-5’UTR-mediated mRNA translation rather than transcription
(Supplementary Fig. S1B, C&D).
In a dose-dependent and stereo-selective manner, PTC299 inhibited hypoxia-induced VEGFA protein
production in HeLa cells with an EC50 of 1.64 ± 0.83 nM (Fig. 1B). Similar activity was also observed
in HT1080 cells which constitutively produce high levels of VEGFA (Supplementary Fig. S1E). The
effect of PTC299 is not limited to secreted isoforms of the protein as the levels of high molecular weight
matrix-bound variants of VEGFA189/206 were similarly decreased (Supplementary Fig. S1F).
PTC-371, the R-enantiomer of PTC299 was inactive in inhibiting VEGFA synthesis.
To verify the role of the VEGFA 5’-UTR for PTC299 activity, a V5 epitope tagged plasmid containing
the VEGFA165 open reading frame was constructed (Fig. 1C, top panel). PTC299 dose-dependently
inhibited VEGF 5’-UTR-mediated production of the VEGFA165-V5 protein as determined by western
blot analysis (Fig. 1C) and by ELISA (Supplementary Fig. S1G). Pulse-chase experiments using
35S-radiolabled methionine and cysteine demonstrated that PTC299 decreased the levels of newly
synthesized VEGFA protein (Fig. 1D) while not decreasing total protein synthesis (Supplementary
Fig. S1H). This effect could not be reversed by treatment with the protein transport blocker brefeldin A
(BFA) or with the proteasome inhibitor MG132 (Supplementary Fig. S1I & 1J). These results suggest
that PTC299 treatment results in the inhibition of VEGFA translation rather than the inhibition of
VEGFA secretion or promotion of VEGFA protein degradation and support the conclusion that the
VEGFA 5’-UTR is required for the suppression of VEGFA mRNA translation by PTC299.
In a mouse tumor xenograft model, PTC299 dose-dependently inhibited the growth of HT1080
fibrosarcoma (Fig. 1E), without overt toxicity or significant body weight changes at any dose when
compared to treatment with the vehicle alone (Supplementary Fig. S1K). In parallel, treatment of mice
with PTC299 resulted in a dose-dependent reduction in the concentrations of intratumor and circulating
plasma human VEGFA relative to those in control mice (Fig. 1F) but had no significant impact on the
11
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
levels of other cytokines such as PDGF and FGF-2 in tumors as assessed in a separate study
(Supplementary Fig. S1L). At the suboptimal dose of 0.3 mg/kg, treatment of mice with PTC299
resulted in partial reductions in the levels of both tumor and plasma human VEGFA, indicating that
inhibition of intra-tumor human VEGFA correlates with tumor growth control.
When stained with anti-murine CD31 antibody, the diameters of tumor vessels were visibly reduced and
their distribution was more uniform in tumors from PTC299-treated mice than in vehicle treated mice
(Fig. 1G), consistent with results in preclinical models using other VEGF-targeted therapies(34, 35).
Inhibition of VEGFA production by PTC299 is a downstream effect of inhibiting de novo
pyrimidine synthesis
To gain insight into the mechanism of action of PTC299, we generated drug-resistant cells by culturing
HT1080 cells in escalating concentrations (1 nM to 1000 nM) of PTC299, doubling the PTC299
concentration weekly. PTC299-resistant HT1080 cells proliferate at a rate similar to that of wild-type
HT1080 cells (Supplementary Fig. S2A), but the IC50 for the inhibition of VEGFA production by
PTC299 in resistant cells is shifted dramatically, from low nM to single digit µM values
(Supplementary Fig. S2B). Transcriptome profiling with microarrays to compare the gene expression
in PTC299-resistant and in parent HT1080 cells demonstrated that the gene with the greatest increase in
expression in PTC299-resistant cells is cytidine deaminase (CDA) while the gene with greatest decrease
is Eukaryotic Translation Initiation Factor 1A, Y-Linked (EIF1AY) (Figure 2A, the microarray data can
be found in Supplementary Excel file-1 or downloaded from GEO database (Accession number:
GSE121266)). These changes in expression were verified by quantitative PCR as shown in
Supplementary Fig S2C. Since CDA is an enzyme in the uridine salvage pathway, we evaluated the
effect of PTC299 treatment on intracellular nucleotide levels. PTC299 selectively decreased the total
levels of the deoxypyrimidine nucleotides dCTP and dTTP, but not those of the deoxypurine nucleotides
dATP and dGTP (Fig. 2B). Metabolic labeling studies using 15N-glutamine demonstrated that PTC299
inhibited de novo pyrimidine synthesis while its inactive R-enantiomer PTC-371 had no effect (Fig.
2C). Further studies demonstrated that inhibition was dose-dependent and measurable after only 30
minutes of treatment (Supplementary Fig. S3 A&B). The inhibition profile of PTC299 in these assays
is similar to that of the known DHODH inhibitor brequinar rather than that of the UMP synthase
(UMPS) inhibitor pyrazofurin-monophosphate (18, 36) (Supplementary Table S2). As shown in Fig.
2D, treatment with pyrazofurin-monophosphate resulted in an over 40-fold increase of 15N-orotate, the
12
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
substrate of UMPS. However, co-treatment with PTC299 blocked the pyrazofurin-MP-induced increase
of 15N-orotate, consistent with inhibition of DHODH that acts upstream of UMPS.
We performed nucleoside rescue studies and demonstrated that the PTC299-mediated inhibition of
VEGFA protein synthesis was dose-dependently blocked by the addition of uridine, but not by the
addition of adenosine, cytidine, or guanosine, to the culture medium (Fig. 2E&F). As a consequence of
DHODH inhibition and subsequent pyrimidine nucleotide depletion, PTC299 also induced an S phase
cell cycle arrest in HT1080 cells (Fig. 2G, 2nd panel). This cell cycle arrest was prevented by the
addition of the pyrimidine nucleosides uridine or cytidine (Fig. 2G, bottom two panels), but not the
purine nucleosides adenosine or guanosine (L. Cao, unpublished observations). These data suggest that
inhibition of VEGFA translation and cell cycle arrest by PTC299 are two separate downstream effects of
inhibiting de novo pyrimidine nucleotide synthesis (Fig. 2H).
PTC299 interacts with and inhibits DHODH activity
Extensive SAR studies demonstrated that a methoxy group on PTC299 can tolerate modification and is
not critical for the biological activity of PTC299 (Y.C. Moon, unpublished observations). By utilizing
this methoxy group, we linked either PTC299, or its inactive R-enantiomer PTC-371, to epoxy-activated
Sepharose 6B (Fig. 3A). In pilot studies, we focused on those highly enriched proteins in PTC299
conjugated bead pull down samples by cutting out the most enriched protein bands for the proteomic
studies and demonstrated that these proteins are Prohibitin-1/2 and voltage-dependent anion channel
(VDAC). After demonstrating that PTC299 inhibits de novo pyrimidine synthesis and has an activity
profile similar to that of the DHODH inhibitor brequinar (Fig. 2 and Supplementary Table S2), we
performed another pull down study and demonstrated that PTC299-beads not only enriched for
prohibitin-1/2 but also for DHODH in the pull-down samples (Fig. 3B). To determine if binding to these
proteins was PTC299 specific, we first performed “compete-on” studies and demonstrated that
pre-incubation with 100 µM PTC299 selectively blocked the binding of DHODH to the PTC299
conjugated beads while it had no effect on the binding of prohibitin-1/2 (Fig. 3C). The inactive
enantiomer PTC-371 had no effect on the binding of either DHODH or Prohibitin 1/2. Similar results
were observed when isolated mitochondrial lysates were used as the protein source (Supplementary
Fig. S3C). We next demonstrated that both free PTC299 and brequinar effectively blocked the binding
of DHODH to the PTC299 conjugated beads while having no effect on prohibitin binding (Fig. 3D),
suggesting that PTC299 and brequinar bind to the same site in DHODH. Subsequently, we performed a
13
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
“competing off” study and demonstrated both PTC299 and brequinar effectively eluted out the DHODH
from the PTC299 conjugated beads while the inactive isomer PTC-371 did not (Fig. 3E), further
supporting the notion that PTC299 and brequinar bind to the same pocket in DHODH. Proteomic study
of those elution samples verified that one of the most selectively enriched proteins was DHODH
(Supplementary Table S3). Since PTC299 is species selective and does not have activity in mouse and
rat cell lines tested in vitro (Supplementary Table S4.), we performed a side by side pull-down study
with human and rat cell lysates. As shown in Fig. 3F, PTC299 conjugated beads enriched for both
human DHODH and prohibitin1/2. However, these beads only bound to rat prohibitin rather than rat
DHODH when compared with the blank beads or the PTC-371 conjugated beads. These data suggest
that PTC299 specifically binds to human DHODH, and that other enriched proteins such as
prohibitin-1/2 are PTC299-bead selective rather than PTC299 specific.
Further studies demonstrated PTC299 inhibited the activity of recombinant DHODH using in vitro
enzyme assays, though not as potently as do brequinar or teriflunomide (Supplementary Fig. S3D).
However, when purified mitochondria were used as the source of DHODH, PTC299 inhibited DHODH
activity more potently than did teriflunomide and with potency similar to that of brequinar (Fig. 3G and
Supplementary Fig. 3E). Along with the result that uridine can completely block the inhibition of
VEGFA production and cell cycle arrest by PTC299, these data indicate that DHODH is the primary
target responsible for the observed activities of PTC299.
Computer modelling shows that PTC299 binds to the same site in DHODH as does brequinar and
with similar strength.
Docking studies on available human DHODH protein (PDB ID: 4IGH, http://www.rcsb.org/) revealed
that PTC299 and the potent brequinar analog C44 bind to the same site with similar strength (Fig. 3H),
consistent with the pull-down results that demonstrated brequinar competes with DHODH binding to
PTC299 beads. The Sybyl Surflex docking score, calculated based on the binding affinity and crash
score(37), is 9.55 for C44 vs 9.27 for PTC299. The interaction of PTC299 with the binding pocket is
mainly a “hand-in-glove” type non-polar hydrophobic interaction. Unlike with C44, there are no H-bond
interactions between PTC299 and Arg136 in DHODH. As anticipated from the pull-down studies, the
inactive enantiomer, PTC-371, bound less efficiently in the pocket with a final docking score of 7.05,
probably because of the unique non-symmetrical shape of the cavity. While PTC299 is a less potent
inhibitor of rhDHODH in vitro, it more potently inhibits DHODH from isolated mitochondria (Fig. 3G
14
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
and supplementary Fig. S3E). Since PTC299 is lipophilic, its entry into the binding pocket of the
enzyme is likely facilitated when the enzyme is embedded in the mitochondrial membrane with
engagement of membrane phospholipids. In studies using purified recombinant protein, there is no
membrane or lipid layer that may hinder the entry of PTC299 into the binding pocket. Efforts to
co-crystallize PTC299 and purified recombinant DHODH have not been successful to date (Nonato MC,
Universidade de São Paulo, Brazil; personal communication), possibly because of the requirement for
the lipid engagement with the enzyme(26). We are currently working to optimize crystallographic
conditions to determine the structure of lipid-engaged DHODH interaction with PTC299.
PTC299 inhibits DHODH activity in patients with neurofibromatosis type 2 (NF2)
Comprehensive preclinical IND-enabling safety pharmacology, toxicology and genotoxicity studies
(Supplementary Materials and Methods in the Supplementary Data file) demonstrated that PTC299 is
safe and well tolerated in pre-clinical studies (Supplementary Table S5). Subsequently, several clinical
trials in healthy volunteers and in patients with solid tumors were conducted to assess PTC299(28, 29),
including a prospective Phase 2a study in 2009-2010 in patients with neurofibromatosis type 2, an
autosomal dominant tumor suppressor syndrome characterized by bilateral vestibular Schwannomas.
Eleven patients were enrolled including 4 males and 7 females with a median age of 25 (range 19-44) at
the time of enrollment. The demographic information on these patients is summarized in
Supplementary Table S6. After 8 weeks of PTC299 treatment, levels of serum VEGFA was
significantly decreased (Fig. 4A, p<0.004, paired Student’s t-test). Baseline levels in healthy volunteers
were reported to be approximately 140 pg/mL(38), indicating that serum VEGFA levels are elevated in
NF2 patients and were reduced by treatment with PTC299 to levels found in healthy volunteers.
Circulating VEGFA was decreased in 11 out of 11 patients as shown in Fig. 4B.
We next examined archived serum samples from some patients in the NF2 clinical study for DHO
levels, hypothesizing that inhibition of DHODH would result in higher levels of this substrate as seen in
patients with genetic deficiency in the DHODH enzyme (39). As shown in Fig. 4C&D, serum DHO
levels in Patient 010-002 who had been on study for 64 weeks, were initially below the lower limit of
quantification. After treatment with PTC299, plasma concentrations of PTC299 and serum levels of
DHO were significantly increased (Fig. 4C) while serum VEGFA protein levels were continuously
decreased (Fig. 4D). For another three patients whose sera were also available at the time the analyses
were performed, DHO levels were also below the lower limit of quantification prior to treatment but
15
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
were significantly increased with PTC299 treatment (Fig. 4E). The increased levels of DHO in these
samples indicate that PTC299 inhibited DHODH in the previous clinical studies.
PTC299 demonstrates broad and potent inhibition of hematologic cancer cell proliferation.
PTC299 inhibits de novo pyrimidine nucleotide synthesis in all cancer cells analyzed whether the cells
are responsive to inhibition of VEGFA production or not (Supplementary Fig. S4). Since pyrimidine
nucleotides can be synthesized by the de novo or the salvage pathway(40), some cancer cells may be
insensitive to PTC299 due to increased pyrimidine nucleotide salvage activity. Thus, we determined the
IC50 (concentration to inhibit cell proliferation by 50%) of PTC299 against a panel of 240 tumor cell
lines. We classified 68 cells lines as responders and 172 cells lines as non-responders based on an
arbitrary IC50 cut-off of 1 µM. Based on these results, sensitivity to PTC299 was observed across
different tumor types (Supplementary Fig. S5A). When grouped as hematopoietic vs solid tumor cells,
57% (32/56) of hematopoietic lines were sensitive to PTC299, whereas only 18% (33/184) in the solid
tumor lines were sensitive to PTC299.
Gene expression of pyrimidine nucleotide synthesis enzymes was analyzed using published microarray
data in the Cancer Cell Line Encyclopedia (CCLE) database(41). Of 240 cell lines tested, 232 were
found in the CCLE database including 54 hematopoietic and 178 solid tumor cell lines. Two salvage
enzymes, cytidine deaminase (CDA) and uridine phosphorylase 1 (UPP1) that convert cytidine and
uracil, respectively, to uridine, were significantly less expressed (3.2-fold for CDA and 4.6-fold for
UPP1) in the hematopoietic tumor lines than in the solid tumor lines (Fig. 5A, and Supplementary
Table S7). We then performed LC-MS/MS analysis of UMP pools from salvage and de novo pathways
in a panel of 8 tumor cell lines and demonstrated that PTC299 sensitive cells in general have less salvage
UMP production relative to de novo UMP production when compared to the insensitive tumor cells
(Fig. 5B). These data suggest that cells with reduced uridine salvage activity are more sensitive to
PTC299.
We then compared the potency of PTC299 in leukemia cells with that of several well-known DHODH
inhibitors(17-19). PTC299 was the most potent inhibitor with an IC50 of about 1 nM, over 10 to
1000-fold more potent than brequinar, vidofludimus or teriflunomide (Fig. 5C), consistent with its
superior potency in the inhibition of VEGFA production in tumor cells (Supplementary Fig. S6). We
also tested PTC299 against acute myeloid leukemia (AML) patient-derived cells. As shown in Fig. 5D,
PTC299 inhibited the proliferation of all five AML patient derived cell lines tested with IC50 values
16
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
ranging from 2 nM to 60 nM. In addition, we have shown that PTC299 induced differentiation in AML
MOLM-13 cells (Supplementary Fig S5B), consistent with the activity of various DHODH inhibitors
as recently reported(14).
After confirming in vitro activity in leukemia cells, we assessed the efficacy of PTC299 in two mouse
models of leukemia. As shown in Fig. 1E, the maximal effect in control of tumor growth and VEGFA
production was achieved at a dose of 3 mg/kg twice daily (BID). Later studies found that once daily
(QD) dosing 10 mg/kg was equivalently effective (M. Weetall, unpublished observation) and thus this
experimentally more feasible dosing regimen was used in the leukemia animal models described below.
In the first model, MOLT-4 human acute lymphoblastic leukemia (ALL) cells were injected
intravenously (IV) into NOD-SCID mice which were then treated with PTC299 or with doxorubicin at
the indicated doses. Doxorubicin was tested at the highest dose tolerated by NOD-SCID mice. As shown
in Fig. 5E, vehicle-dosed mice had a median survival time (MST) of 46 days and did not survive beyond
71 days. Doxorubicin did not prolong survival time. The MST for the mice dosed with PTC299 was 136
days (p<0.05, one-way ANOVA, multiple comparisons vs vehicle). The number of circulating MOLT-4
cells was significantly reduced in mice treated with PTC299 but not in mice treated with doxorubicin
(Supplementary Fig. S5C).
In a second study, MOLM-13 AML cells were injected into the flank of nude mice to generate a solid
tumor. Cytarabine (AraC) is a deoxycytidine analog used as a standard chemotherapeutic agent to treat
AML(42). As shown in Fig. 5F, PTC299 treatment alone resulted in a significant delay of tumor growth
when compared with vehicle or AraC treatment; the median time to reach a tumor volume of 1000 mm3
was 23 days for PTC299 vs 7 and 13 days for vehicle and AraC treated mice, respectively. The
combination of PTC299 with AraC further delayed tumor growth for 39 days. The increased activity of
the combination of AraC with PTC299 may reflect a more efficient incorporation of AraC into DNA due
to a reduction in the levels of competing endogenous pyrimidine nucleotides.
DISCUSSION
Tumor cells require the upregulation and integration of multiple biosynthetic processes including
synthesis of nucleotides and proteins to drive uncontrolled cell proliferation(43). Here, we demonstrate
that decreased translation of VEGFA mRNA by PTC299 is linked to the inhibition of de novo
pyrimidine nucleotide synthesis as exogenously added uridine, but not other nucleosides, can
completely block the inhibition of VEGFA production by PTC299. Unlike uridine, cytidine only
17
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
rescued the cell cycle arrest in S-phase but not the inhibition of VEGFA production. This discrepancy
may be due to the lower levels of CDA expression (Fig. 2A and Supplementary Fig. S2C) and cytidine
could not be efficiently converted to uridine in the HT1080 cells. Moreover, exogenously added cytidine
in cells expressing low levels of CDA could be quickly converted to CTP/dCTP which in turn might
further inhibit the CDA and other salvage enzymes (44, 45).
Extensive biological characterization demonstrated that DHODH is the primary target of PTC299 as all
the observed activities of PTC299 can be completely rescued by addition of exogenous uridine rather
than other nucleosides. The proteomic study showed other potential targets may exist, and the selectivity
and significance of those proteins identified in the proteomic study warrant further investigation.
Similar to PTC299, other DHODH inhibitors such as brequinar also inhibit VEGFA production albeit
less potently (Supplementary Fig. S6B&C). The link between the inhibition of VEGFA mRNA
translation and de novo pyrimidine synthesis was unanticipated but may be critical for cancer cells to
synchronize rapid proliferation and angiogenesis for tumor progression. Inhibition of VEGFA mRNA
translation by PTC299 is mediated by the 5’-UTR of the mRNA prompting multiple hypotheses for this
link: 1) Depletion of uridine nucleotide pools may affect certain translation initiation factor(s) required
for the non-canonical protein synthesis of stress-regulated mRNAs such as the VEGFA mRNA. We
observed that eIF1AY gene expression decreased over 90% in PTC299-resistant HT1080 cells, when
compared with wild type HT1080 cells (Fig. 2A and Supplementary Fig. 2). eIF1A controls translation
start codon recognition and has been reported to affect IRES-mediated translation(46); 2) Low levels of
uridine nucleotides may also affect the mRNA substrate directly. For example, depletion of pyrimidine
nucleotides in cancer cells can cause a starvation-like stress response which may lead to changes in
pseudouridylation state of mRNA(47). Reduction of dyskerin expression, a component of
pseudouridine synthase has been shown to selectively increase VEGFA-IRES mediated translation(48).
As uridines in RNAs are substrates for dyskerin, depletion of uridine nucleotides by PTC299 may
reduce free substrate competition and thus activate dyskerin to inhibit VEGFA mRNA translation; and
3) A recent study has demonstrated that the activity of mTOR, which controls synthesis of proteins and
nucleotides(5), can be regulated by nucleotide pools(49). Thus, it is also possible that inhibition of the
translation of regulated mRNAs, such as the VEGFA mRNA, is mediated via disrupting the production
of pyrimidine nucleotides causing imbalances in nucleotide pools. Elucidating the molecular
mechanisms linking inhibition of DHODH and VEGFA mRNA translation requires further
investigation.
18
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
Two inhibitors of human DHODH have been approved for use in autoimmune diseases, leflunomide for
rheumatoid arthritis and its active metabolite, teriflunomide for multiple sclerosis(50). Brequinar,
another potent inhibitor of human DHODH was tested in the 1990s in clinical trials for solid tumors but
was associated with myeloid suppression and had a limited therapeutic window (18, 22). These DHODH
inhibitors are associated with side-effects believed to be due to their off-target activities such as
inhibition of kinases (21, 22). Recently, the inhibition of DHODH by GSK983, which is structurally
related to PTC299, was reported (51). However, we determined that this compound has a considerably
lower bioavailability in mice than does PTC299 (Supplementary Fig. S7).
PTC299 represents a novel class of DHODH inhibitors with favorable biochemical and pharmacological
properties that may distinguish it from previously published DHODH inhibitors: 1) Unlike the
well-known DHODH inhibitors teriflunomide and brequinar, PTC299 did not show off-target effects
including any overt effects on 205 kinases and 62 Novascreen pharmacological targets tested
(Supplementary Table S5) and did not result in myeloid suppression in patients with solid tumors(28,
29); 2) PTC299 has been extensively tested and well-tolerated in preclinical studies. PTC299 did not
inhibit the proliferation of normal primary cells including hematopoietic stem cells at concentrations
1000-fold greater than its IC50 in tumor cells (Supplementary Table S5); 3) DHODH inhibitors were
identified by others using in vitro enzymatic assay in which the purified enzyme conformation may
differ from that found in the cells due to lack of lipids in the assay(25, 26). The potent activity of
PTC299 in mitochondrial preparations is likely due to the presence of the lipid bilayer when the enzyme
is in the mitochondrial membrane that may facilitate the entry and/or docking of the lipophilic PTC299
into the binding pocket of the DHODH enzyme. This is consistent with the recent reports that
interactions with the small lipophilic pocket in DHODH are critical for potent inhibition of its enzymatic
activity(23, 26); 4) PTC299-resistant HT1080 cells are not cross-resistant to DHODH inhibitors such
as brequinar or teriflunomide (Supplementary Fig. S6), indicating that the mode of action for PTC299
is different from that of other DHODH inhibitors even though they target the same docking site; 5) It
was demonstrated that inhibition of DHODH activates p53 expression resulting in inhibition of cancer
cell proliferation and apoptosis (11). However, we analyzed the p53 expression in the CCLE database
and found no correlation of p53 expression with the activity of PTC299 (IC50) in those cell lines. Dr.
Kensuke Kojima (Kyoto University, Japan) tested PTC299 in a panel of leukemia cell lines and also
found that PTC299 activity does not correlate with the expression of p53 (personal communication); and
finally, 6) a docking model shows that PTC299 binds DHODH in the same pocket and with similar
19
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
strength as does brequinar analog C44. However, the interaction of PTC299 with the binding pocket is
mainly a “hand-in-glove”, non-polar lipophilic interaction (Fig. 3H). These findings demonstrate that
PTC299 is structurally and functionally different from previously published DHODH inhibitors, thus it
may be a useful new tool for preclinical and clinical investigation of targeting DHODH for therapeutic
uses in treatment of cancer and immune diseases.
The elucidation of the mechanism of action of PTC299 will facilitate the optimization of biomarker
identification, patient selection and design of combination therapies with other drug(s) for clinical
development. Here our data together point to the potential clinical utility of PTC299 for the treatment
of cancers such as leukemia and lymphoma which in general have lower pyrimidine salvage activity
and thus depend on de novo pyrimidine synthesis for uncontrolled proliferation. PTC299 was placed
on clinical hold following the occurrence of severe hepatotoxicity in two patients out of 279 individuals
administered with PTC299(28, 29). Based on recent preclinical assessments demonstrating antitumor
activity in AML models at low doses of PTC299, we are reevaluating the potential use of PTC299 in
leukemia and lymphoma, anticipating that efficacious concentration of PTC299 will be lower than
those achieved in previous clinical studies in solid tumors.
Conclusion
PTC299 is a novel potent inhibitor of DHODH that is differentiated from and has advantages over other
DHODH inhibitors. Studies demonstrated the target engagement of PTC299 in patients, thus
supporting its potential for treatment of hematologic malignancies which rely on de novo pyrimidine
nucleotide synthesis for survival and proliferation.
Acknowledgments
We thank all the members of the Discovery group at PTC for the thoughtful discussion and constructive
advises throughout the PTC299 program. We thank Jana Narasimhan for a critical reading and
discussion of this manuscript. This program was partially supported by funding from National Cancer
Institute (NCI) to J.M. Colacino and L. Cao (2 R44 CA108330-02).
20
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
Reference List
(1) Martinez-Outschoorn UE, Peiris-Pages M, Pestell RG, Sotgia F, Lisanti MP. Cancer
metabolism: a therapeutic perspective. Nat Rev Clin Oncol 2017;14:113.
(2) Brown KK, Spinelli JB, Asara JM, Toker A. Adaptive Reprogramming of De Novo
Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer. Cancer
Discov 2017;7:391-9.
(3) McMahon SB. Control of nucleotide biosynthesis by the MYC oncoprotein. Cell Cycle
2008;7:2275-6.
(4) Mathur D, Stratikopoulos E, Ozturk S, Steinbach N, Pegno S, Schoenfeld S, et al. PTEN
Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate
Dehydrogenase Inhibition. Cancer Discov 2017;7:380-90.
(5) Robitaille AM, Christen S, Shimobayashi M, Cornu M, Fava LL, Moes S, et al. Quantitative
phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science
2013;339:1320-3.
(6) Rawls J, Knecht W, Diekert K, Lill R, Loffler M. Requirements for the mitochondrial import
and localization of dihydroorotate dehydrogenase. Eur J Biochem 2000;267:2079-87.
(7) Vyas VK, Ghate M. Recent developments in the medicinal chemistry and therapeutic
potential of dihydroorotate dehydrogenase (DHODH) inhibitors. Mini Rev Med Chem
2011;11:1039-55.
(8) Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML. Broad-spectrum antiviral that
interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A
2011;108:5777-82.
(9) Koundinya M, Sudhalter J, Courjaud A, Lionne B, Touyer G, Bonnet L, et al. Dependence on
the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant
KRAS-Driven Cancers. Cell Chem Biol 2018.
(10) Mohamad Fairus AK, Choudhary B, Hosahalli S, Kavitha N, Shatrah O. Dihydroorotate
dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate
S-phase arrest in breast cancer cells. Biochimie 2017;135:154-63.
(11) Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, et al. A
DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53
degradation blockage. Nat Commun 2018;9:1107.
(12) Dorasamy MS, Choudhary B, Nellore K, Subramanya H, Wong PF. Dihydroorotate
dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma
cells at S-phase. J Cancer 2017;8:3086-98.
21
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
(13) Zhang X, Yang J, Chen M, Li L, Huan F, Li A, et al. Metabolomics profiles delineate uridine
deficiency contributes to mitochondria-mediated apoptosis induced by celastrol in human
acute promyelocytic leukemia cells. Oncotarget 2016;7:46557-72.
(14) Sykes DB, Kfoury YS, Mercier FE, Wawer MJ, Law JM, Haynes MK, et al. Inhibition of
Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid
Leukemia. Cell 2016;167:171-86.
(15) Lewis TA, Sykes DB, Law JM, Munoz B, Rustiguel JK, Nonato MC, et al. Development of
ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid
Leukemia. ACS Med Chem Lett 2016;7:1112-7.
(16) Wu D, Wang W, Chen W, Lian F, Lang L, Huang Y, et al. Pharmacologic inhibition of
dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid
leukemia cells. Haematologica 2018.
(17) Baumann P, Mandl-Weber S, Volkl A, Adam C, Bumeder I, Oduncu F, et al. Dihydroorotate
dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes
proliferation of multiple myeloma cells. Mol Cancer Ther 2009;8:366-75.
(18) Cody R, Stewart D, DeForni M, Moore M, Dallaire B, Azarnia N, et al. Multicenter phase II
study of brequinar sodium in patients with advanced breast cancer. Am J Clin Oncol
1993;16:526-8.
(19) Fitzpatrick LR, Small JS, Doblhofer R, Ammendola A. Vidofludimus inhibits colonic
interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. J
Pharmacol Exp Ther 2012;342:850-60.
(20) Arteaga CL, Brown TD, Kuhn JG, Shen HS, O'Rourke TJ, Beougher K, et al. Phase I clinical
and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390). Cancer Res
1989;49:4648-53.
(21) Xu X, Williams JW, Gong H, Finnegan A, Chong AS. Two activities of the
immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine
nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol
1996;52:527-34.
(22) Xu X, Williams JW, Shen J, Gong H, Yin DP, Blinder L, et al. In vitro and in vivo
mechanisms of action of the antiproliferative and immunosuppressive agent, brequinar
sodium. J Immunol 1998;160:846-53.
(23) Sainas S, Pippione AC, Giorgis M, Lupino E, Goyal P, Ramondetti C, et al. Design,
synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate
dehydrogenase inhibitors based on hydroxylated azole scaffolds. Eur J Med Chem
2017;129:287-302.
22
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
(24) Lucas-Hourani M, Munier-Lehmann H, El MF, Malmquist NA, Harpon J, Coutant EP, et al.
Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate
Dehydrogenase (DHODH). J Med Chem 2015;58:5579-98.
(25) Basso LGM, Mendes LFS, Costa-Filho AJ. The two sides of a lipid-protein story. Biophys
Rev 2016;8:179-91.
(26) Costeira-Paulo J, Gault J, Popova G, Ladds MJGW, van Leeuwen IMM, Sarr M, et al. Lipids
Shape the Electron Acceptor-Binding Site of the Peripheral Membrane Protein
Dihydroorotate Dehydrogenase. Cell Chem Biol 2018;25:309-17.
(27) Cao L, Weetall M, Bombard J, Qi H, Arasu T, Lennox W, et al. Discovery of Novel Small
Molecule Inhibitors of Expression in Tumor Cells Using a Cell-Based High Throughput
Screening Platform. PLoS One 2016;11:e0168366.
(28) Weetall M, Davis T, Elfring G, Northcutt V, Cao L, Moon YC, et al. Phase 1 Study of Safety,
Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein
Translation. Clin Pharmacol Drug Dev 2016;5:296-305.
(29) Packer RJ, Rood BR, Turner DC, Stewart CF, Fisher M, Smith C, et al. Phase I and
pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central
nervous system tumors: a PBTC study. J Neurooncol 2015;121:217-24.
(30) Clayton DA, Shadel GS. Isolation of mitochondria from cells and tissues. Cold Spring Harb
Protoc 2014;2014:db.
(31) Chen SF, Perrella FW, Behrens DL, Papp LM. Inhibition of dihydroorotate dehydrogenase
activity by brequinar sodium. Cancer Res 1992;52:3521-7.
(32) Ruppert J, Welch W, Jain AN. Automatic identification and representation of protein
binding sites for molecular docking. Protein Sci 1997;6:524-33.
(33) Cheatham TE, III, Cieplak P, Kollman PA. A modified version of the Cornell et al. force
field with improved sugar pucker phases and helical repeat. J Biomol Struct Dyn
1999;16:845-62.
(34) Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, et al. Antivascular endothelial
growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis
and growth of several mouse and human tumors. Cancer Res 1999;59:5209-18.
(35) Lichtenbeld HC, Ferarra N, Jain RK, Munn LL. Effect of local anti-VEGF antibody
treatment on tumor microvessel permeability. Microvasc Res 1999;57:357-62.
(36) Ohnuma T, Roboz J, Shapiro ML, Holland JF. Pharmacological and biochemical effects of
pyrazofurin in humans. Cancer Res 1977;37:2043-9.
(37) Jain AN. Effects of protein conformation in docking: improved pose prediction through
protein pocket adaptation. J Comput Aided Mol Des 2009;23:355-74.
23
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
(38) Di RF, Azzaro MP, Palumbo GA, Bagnato S, Stagno F, Giustolisi GM, et al. Elevated
vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis.
Leukemia 2001;15:976-80.
(39) Duley JA, Henman MG, Carpenter KH, Bamshad MJ, Marshall GA, Ooi CY, et al. Elevated
plasma dihydroorotate in Miller syndrome: Biochemical, diagnostic and clinical
implications, and treatment with uridine. Mol Genet Metab 2016;119:83-90.
(40) Lane AN, Fan TW. Regulation of mammalian nucleotide metabolism and biosynthesis.
Nucleic Acids Res 2015;43:2466-85.
(41) Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer
Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature
2012;483:603-7.
(42) Wang X, Harrison JS, Studzinski GP. Enhancement of arabinocytosine (AraC) toxicity to
AML cells by a differentiation agent combination. J Steroid Biochem Mol Biol
2016;164:72-8.
(43) Cunningham JT, Moreno MV, Lodi A, Ronen SM, Ruggero D. Protein and nucleotide
biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell
2014;157:1088-103.
(44) Ipata PL, Falcone G, Serra MC. Some regulatory properties of cytidine deaminase and
uridine phosphorylase of Bacillus cereus. FEBS Lett 1970;10:67-70.
(45) Gemble S, Ahuja A, Buhagiar-Labarchede G, Onclercq-Delic R, Dairou J, Biard DS, et al.
Pyrimidine Pool Disequilibrium Induced by a Cytidine Deaminase Deficiency Inhibits
PARP-1 Activity, Leading to the Under Replication of DNA. PLoS Genet
2015;11:e1005384.
(46) Jaafar ZA, Oguro A, Nakamura Y, Kieft JS. Translation initiation by the hepatitis C virus
IRES requires eIF1A and ribosomal complex remodeling. Elife 2016;5.
(47) Wu G, Radwan MK, Xiao M, Adachi H, Fan J, Yu YT. The TOR signaling pathway
regulates starvation-induced pseudouridylation of yeast U2 snRNA. RNA 2016;22:1146-52.
(48) Rocchi L, Pacilli A, Sethi R, Penzo M, Schneider RJ, Trere D, et al. Dyskerin depletion
increases VEGF mRNA internal ribosome entry site-mediated translation. Nucleic Acids
Res 2013;41:8308-18.
(49) Emmanuel N, Ragunathan S, Shan Q, Wang F, Giannakou A, Huser N, et al. Purine
Nucleotide Availability Regulates mTORC1 Activity through the Rheb GTPase. Cell Rep
2017;19:2665-80.
(50) Schiff MH, Strand V, Oed C, Loew-Friedrich I. Leflunomide: efficacy and safety in clinical
trials for the treatment of rheumatoid arthritis. Drugs Today (Barc ) 2000;36:383-94.
24
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
(51) Deans RM, Morgens DW, Okesli A, Pillay S, Horlbeck MA, Kampmann M, et al. Parallel
shRNA and CRISPR-Cas9 screens enable antiviral drug target identification. Nat Chem Biol
2016;12:361-6.
25
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
Figure legends
Figure 1. Structure, biological activity and stereoselectivity of PTC299. (A) Chemical structure of
PTC299, the 1S configuration and the inactive R enantiomer, PTC-371. (B) PTC299 inhibits
hypoxia-induced VEGFA expression in HeLa cells. Results are expressed as the percent inhibition of
hypoxia induced VEGFA production relative to vehicle-treated controls. Hypoxia (1% oxygen) induced
VEGFA production is measured by subtracting the VEGFA produced under normoxic conditions (21%
oxygen) from the levels of VEGFA produced under hypoxia. Data are mean ± SD from a representative
study (n = 3). (C) The VEGFA 5’-UTR is required for PTC299 inhibition of a V5-tagged VEGFA165
protein production. HT1080 cells were stably transfected with the constructs shown in the diagrams on
the top of the graph. The culture supernatant and cell lysates were collected for western blot after
treatment with PTC299 or 0.5% DMSO control for 36 hours. (D) PTC299 selectively inhibits
35
production of pulse S labeled VEGFA. The VEGFA-V5 stable cell lines were treated with PTC299
(100 nM) for 8 hours and then pulsed/chased with 35S-radiolabled methionine and cysteine for 4 hours
prior to immunoprecipitation with V5 antibody. (E) PTC299 dose-dependently inhibits HT1080 tumor
growth in mice. Values represent the average ± SEM of 10 mice per group. Compound or vehicle was
orally administered twice daily (BID) as indicated in the graph. ** p < 0.001, One-way ANOVA test. (F)
PTC299 reduces intra-tumor and serum levels of human VEGFA. Values represent the average ± SEM
of 10 mice. One-way ANOVA test compared to vehicle, * indicates p < 0.05, ** p < 0.001. (G) PTC299
inhibits tumor angiogenesis, tumor sections were stained with anti-CD31 antibody.
Figure 2. Inhibition of VEGFA translation by PTC299 is coupled with inhibition of de novo
pyrimidine synthesis. (A) Transcriptome profiling of PTC299-resistant HT1080 cells using
microarrays. Highlighted on the left volcano plot are those genes with greater than 2-fold changes in
expression with a false discovery rate (FDR) less than 0.05; the heat maps of the expression of these
genes are shown on the right. (B) PTC299 selectively decreases pyrimidine nucleotides in HT1080
cells. HT1080 cells were treated with PTC299 (100 nM) or 0.5% DMSO control for 8 hours. Data are
representative of two independent studies. (C) PTC299 inhibits de novo pyrimidine nucleotide
synthesis. HT1080 cells in log phase growth were treated with compounds (100 nM) or vehicle control
15
15
(0.5% DMSO) in the presence of 1 mM N-glutamine for 8 hours. N-labelled CTP, UTP and UMP
were quantified with LC/MS. Data are representative of two independent studies. (D) PTC299 acts
upstream of UMPS. Cells were treated with 1 µM PTC299 or MP-pyrazofurin or combination of the two
for 8 hours. Peak area ratio of orotic acid (normalized to an internal control) for each treatment was
26
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
determined and average ± SD was shown in the picture (n = 2). MP-pyrazofurin is a UMPS inhibitor; (E)
Inhibition of VEGFA production in HT1080 cells by PTC299 is completely blocked by addition of
exogenous uridine into the cell culture. Cells were treated with PTC299 (100 nM) or vehicle (0.5%
DMSO) in the presence of 100 µM various nucleosides (indicated in the figure) for 48 hours. Data are
mean ± SD, n = 2. (F) Inhibition of VEGFA production in HT1080 cells by PTC299 is dose-dependently
blocked by addition of exogenous uridine. Assays were done in triplicate, and data represent average
inhibition against DMSO control after VEGFA levels normalized to viable cell number measured by
Celltiter-Glo. Data represent the mean ± SD, n = 2. (G) Cell cycle arrest in S-phase induced by PTC299
is completely blocked by addition of exogenous uridine or cytidine into the cell culture. HT1080 Cells
were treated with PTC299 (100 nM) or vehicle (0.5% DMSO) in the presence of 100 µM of the
indicated nucleosides for 24 hours. (H) A scheme showing de novo and salvage pathways of pyrimidine
nucleotide synthesis. CDA: cytidine deaminase; UPP: Uridine phosphorylase; UCK: uridine cytidine
kinase; CAD: Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase;
UMPS: UMP synthase.
Figure 3. PTC299 binds to and inhibits the activity of DHODH. (A) Schematic drawing of PTC299,
the inactive isomer linked to the agarose beads and the outline of chemical pulldown study; (B) PTC299
beads bind to DHODH and prohibitin-1/2. Pull-down samples from Blank, PTC-371 and PTC299
conjugated beads were resolved on 4-20% SDS-PAGE. Left panel shows the silver staining, while the
right panel shows westerns blotted with antibodies against human DHODH, PHB1 (prohibitin-1), PHB2
(prohibitin-2) and VDAC (voltage-dependent anion channel) respectively; (C) PTC299 selectively
inhibits DHODH binding to the PTC299-beads. HT1080 cell lysates were preincubated with 100 µM
free PTC299 or PTC-371 as indicated in the figure for 2 hours at 4oC prior to the pull-down study
described in the methods; (D) Western blot analysis demonstrated that free PTC299 and brequinar
competes DHODH binding to the PTC299-beads. The experiment was done in the same way as for
Fig.3C. (E) Western blot analysis demonstrated that free PTC299 selectively elutes DHODH from the
PTC299-beads; (F) PTC299 conjugated beads selective bind to human rather than rat DHODH; (G)
PTC299 inhibits DHODH activity in isolated mitochondria, data are representative of three independent
mitochondria preparations, orotate production was quantified by LC-MS/MS analysis of the end product
after 30 minutes enzyme reaction. (H) Computer modelling using crystal structures of the human
DHODH protein. Both the brequinar analog C44 (Purple) and PTC299 (cyan) bind deep in the pocket,
but the inactive enantiomer PTC-371 (orange) does not, which is reflected by the docking scores on the
27
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
right. The cofactor flavin mononucleotide (FMN) and the product orotate are shown in yellow and blue
respectively. Right panel shows a localized view that PTC299 (cyan) binds to the pocket of human
DHODH crystal at 4IGH. Amino acids within 5 angstroms of PTC299 are shown as a ribbon. Amino
acid residues within 3 angstroms were labeled (hydrophobic, brown; charged, purple; polar, blue).
Relevant side chains that make up the pocket are displayed explicitly.
Figure 4. PTC299 inhibits DHODH activity and reduces elevated VEGFA levels in patients with
neurofibromatosis type 2. (A) Reduction in mean levels of serum VEGFA after 8 weeks of PTC299
treatment; Data are represented as mean ± SEM, n = 11. (B) VEGFA reduction for individual patients
over the course of the PTC299 treatment; (C) Serum levels of DHO are correlated with PTC299
concentration in patient-002; (D) Serum levels of DHO are inversely correlated with serum VEGFA
levels in patient-002. (E) PTC299 increases serum DHO in three additional patients whose serum
samples were still available at the time of analysis. BLQ: below the level of quantification.
Figure 5. PTC299 demonstrates broad activity and potent inhibition of leukemia cell
proliferation in vitro and in animal models. (A) Box-plot of log2 expression level (microarray) for
CDA and UPP1, two pyrimidine salvage enzymes for converting cytidine and uracil, respectively, to
uridine. The box represents the lower and upper quartile of the data. The white line in the box represents
the median value. The whiskers represent the extension of data up to 1.5x of interquartile range (IQR)
below the lower quartile or above the upper quartile. P-values are calculated with Software R
(https://www.r-project.org/, version 3.3.1) based on t-test comparing hematopoietic tumors (n = 54)
and solid tumors (n = 178); (B) PTC299 sensitive cells in general have less salvage UMP production.
Four sensitive (HeLa, HT1080, A549 and K562) and four insensitive lines (U87MG, MCF7, PC3 and
Huh7) were cultured in the presence of 15N-Glutamine for 8 hours, then the unlabeled and 15N-labeled
UMP in the cell lysates were measured by LC-MS/MS analysis. Data are mean ± SEM, n = 4, p value
from t-test. (C) PTC299 inhibits the proliferation of MOLM13 AML cells more potently than do other
known DHODH inhibitors. Cells were treated with indicated compounds for 72 hours and cell
proliferation was measured Celltiter Glo (Promega). % inhibition was calculated against the vehicle
(0.5% DMSO) treatment. Data are mean ± SD, n = 2. (D) PTC299 is active in all five AML
patient-derived cells in vitro. Patient-derived AML cells were treated with PTC299 for 72 hours and
then cell proliferation was assessed using Celltiter Glo (Promega); Assays were done in duplicate
(AML-002,004 and 005) or triplicate (AML-001 and 003). (E) PTC299 prolongs survival of mice
bearing human acute lymphoid leukemia (ALL) after IV inoculation of NOD/SCID mice with MOLT-4
28
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Liangxian Cao et.al.
cells (10 mice/group), Treatment with PTC299 (10 mg/kg, qd), or with doxorubicin (0.5 mg/kg or 1
mg/kg IP once per week), was initiated 7 days after tumor inoculation; (F) PTC299 inhibits MOLM-13
acute myeloid leukemia xenograft tumor growth in nude mice. Values shown represent the mean of 8
mice per group and error bars show the standard error of the mean.
29
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.

Author Manuscript Published OnlineFirst on October 23, 2018; DOI: 10.1158/1535-7163.MCT-18-0863
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Downloaded from mct.aacrjournals.org on November 2, 2018. © 2018 American Association for Cancer Research.